| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 138 | 2024 | 640 | 20.700 |
Why?
|
| Deep Brain Stimulation | 45 | 2023 | 351 | 8.000 |
Why?
|
| Anxiety Disorders | 26 | 2024 | 684 | 2.410 |
Why?
|
| Psychiatric Status Rating Scales | 29 | 2022 | 905 | 2.130 |
Why?
|
| Mental Disorders | 17 | 2023 | 870 | 2.080 |
Why?
|
| Tourette Syndrome | 14 | 2023 | 130 | 2.010 |
Why?
|
| Transcranial Magnetic Stimulation | 10 | 2023 | 76 | 1.970 |
Why?
|
| Psychometrics | 25 | 2023 | 950 | 1.880 |
Why?
|
| Emotions | 13 | 2023 | 568 | 1.700 |
Why?
|
| Connectome | 3 | 2023 | 115 | 1.500 |
Why?
|
| Surveys and Questionnaires | 31 | 2022 | 5724 | 1.500 |
Why?
|
| Implosive Therapy | 6 | 2020 | 78 | 1.450 |
Why?
|
| Brain | 20 | 2023 | 4097 | 1.420 |
Why?
|
| Parents | 17 | 2024 | 1003 | 1.320 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 10 | 2022 | 234 | 1.310 |
Why?
|
| Adolescent | 87 | 2024 | 31239 | 1.260 |
Why?
|
| Anxiety | 21 | 2023 | 1188 | 1.210 |
Why?
|
| Streptococcal Infections | 6 | 2011 | 281 | 1.200 |
Why?
|
| Cerebral Cortex | 5 | 2018 | 624 | 1.180 |
Why?
|
| Tic Disorders | 6 | 2019 | 65 | 1.160 |
Why?
|
| Severity of Illness Index | 38 | 2022 | 4355 | 1.160 |
Why?
|
| Antipsychotic Agents | 7 | 2019 | 412 | 1.130 |
Why?
|
| Prefrontal Cortex | 11 | 2023 | 231 | 1.100 |
Why?
|
| Humans | 207 | 2024 | 262248 | 1.030 |
Why?
|
| Psychiatry | 2 | 2023 | 298 | 1.000 |
Why?
|
| Attention | 4 | 2019 | 275 | 0.990 |
Why?
|
| Interoception | 3 | 2018 | 5 | 0.980 |
Why?
|
| Nerve Net | 4 | 2021 | 257 | 0.980 |
Why?
|
| Subthalamic Nucleus | 3 | 2021 | 57 | 0.970 |
Why?
|
| Child | 72 | 2024 | 29067 | 0.910 |
Why?
|
| Septal Nuclei | 1 | 2023 | 9 | 0.910 |
Why?
|
| Depression | 18 | 2023 | 1730 | 0.880 |
Why?
|
| Depressive Disorder, Major | 9 | 2024 | 431 | 0.870 |
Why?
|
| Tics | 4 | 2010 | 48 | 0.830 |
Why?
|
| Fluoxetine | 4 | 2009 | 43 | 0.810 |
Why?
|
| Personality Inventory | 10 | 2010 | 179 | 0.810 |
Why?
|
| Emergency Shelter | 2 | 2019 | 9 | 0.800 |
Why?
|
| Internal Capsule | 6 | 2023 | 40 | 0.800 |
Why?
|
| Treatment Outcome | 51 | 2024 | 33028 | 0.760 |
Why?
|
| Streptococcus pyogenes | 4 | 2011 | 119 | 0.750 |
Why?
|
| Psychosurgery | 3 | 2023 | 28 | 0.750 |
Why?
|
| Male | 107 | 2024 | 123338 | 0.740 |
Why?
|
| Cycloserine | 4 | 2019 | 25 | 0.720 |
Why?
|
| Adult | 77 | 2023 | 78179 | 0.710 |
Why?
|
| Antidepressive Agents | 8 | 2018 | 322 | 0.690 |
Why?
|
| Female | 106 | 2024 | 142293 | 0.670 |
Why?
|
| Serotonin Antagonists | 1 | 2018 | 39 | 0.650 |
Why?
|
| Ondansetron | 1 | 2018 | 41 | 0.650 |
Why?
|
| Parkinson Disease | 6 | 2023 | 710 | 0.640 |
Why?
|
| Suicide | 5 | 2023 | 185 | 0.640 |
Why?
|
| Anhedonia | 4 | 2024 | 40 | 0.630 |
Why?
|
| Civil Defense | 1 | 2018 | 13 | 0.630 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2018 | 22 | 0.620 |
Why?
|
| Cognition | 6 | 2022 | 973 | 0.610 |
Why?
|
| Electroconvulsive Therapy | 2 | 2016 | 59 | 0.590 |
Why?
|
| Citalopram | 3 | 2005 | 35 | 0.580 |
Why?
|
| Factor Analysis, Statistical | 11 | 2019 | 358 | 0.580 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2023 | 90 | 0.580 |
Why?
|
| Olfactory Perception | 1 | 2017 | 31 | 0.570 |
Why?
|
| Reproducibility of Results | 20 | 2022 | 6046 | 0.570 |
Why?
|
| Disasters | 1 | 2018 | 109 | 0.560 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 218 | 0.540 |
Why?
|
| Interview, Psychological | 2 | 2013 | 102 | 0.540 |
Why?
|
| Brain Mapping | 8 | 2023 | 648 | 0.520 |
Why?
|
| Nucleus Accumbens | 4 | 2010 | 62 | 0.520 |
Why?
|
| Comorbidity | 13 | 2024 | 2397 | 0.520 |
Why?
|
| Mental Health Services | 1 | 2018 | 223 | 0.510 |
Why?
|
| Signal Detection, Psychological | 2 | 2014 | 10 | 0.510 |
Why?
|
| Visual Cortex | 1 | 2016 | 136 | 0.500 |
Why?
|
| Hearing Disorders | 3 | 2023 | 31 | 0.500 |
Why?
|
| Trichotillomania | 2 | 2014 | 32 | 0.500 |
Why?
|
| Family | 6 | 2022 | 735 | 0.500 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 136 | 0.490 |
Why?
|
| Cyclonic Storms | 3 | 2022 | 90 | 0.480 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2014 | 31 | 0.480 |
Why?
|
| Neurosciences | 2 | 2019 | 51 | 0.480 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2020 | 269 | 0.470 |
Why?
|
| Autoimmune Diseases | 2 | 2011 | 405 | 0.470 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 3 | 2008 | 41 | 0.460 |
Why?
|
| Depressive Disorder | 6 | 2016 | 562 | 0.450 |
Why?
|
| Behavior Therapy | 3 | 2020 | 300 | 0.450 |
Why?
|
| Quality of Life | 12 | 2023 | 4582 | 0.450 |
Why?
|
| Awareness | 2 | 2017 | 123 | 0.440 |
Why?
|
| Models, Neurological | 1 | 2014 | 225 | 0.440 |
Why?
|
| Thalamus | 3 | 2023 | 134 | 0.440 |
Why?
|
| Sertraline | 4 | 2015 | 45 | 0.430 |
Why?
|
| Neurosurgery | 3 | 2023 | 109 | 0.430 |
Why?
|
| Affect | 1 | 2014 | 293 | 0.430 |
Why?
|
| Habenula | 3 | 2018 | 44 | 0.420 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 78 | 0.410 |
Why?
|
| Survivors | 1 | 2018 | 1035 | 0.410 |
Why?
|
| Young Adult | 19 | 2022 | 21494 | 0.400 |
Why?
|
| Middle Aged | 43 | 2022 | 86544 | 0.380 |
Why?
|
| Artifacts | 3 | 2023 | 532 | 0.380 |
Why?
|
| Drug Discovery | 4 | 2010 | 326 | 0.380 |
Why?
|
| Adaptation, Psychological | 4 | 2021 | 772 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 7717 | 0.370 |
Why?
|
| Mental Health | 4 | 2023 | 409 | 0.370 |
Why?
|
| Neuropsychological Tests | 7 | 2017 | 1175 | 0.370 |
Why?
|
| Implantable Neurostimulators | 2 | 2020 | 18 | 0.360 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2024 | 642 | 0.350 |
Why?
|
| Attitude | 3 | 2020 | 161 | 0.340 |
Why?
|
| Gyrus Cinguli | 4 | 2023 | 140 | 0.340 |
Why?
|
| Child Behavior Disorders | 6 | 2009 | 69 | 0.340 |
Why?
|
| Smiling | 2 | 2010 | 16 | 0.340 |
Why?
|
| Combined Modality Therapy | 14 | 2021 | 8885 | 0.340 |
Why?
|
| Mood Disorders | 3 | 2023 | 162 | 0.320 |
Why?
|
| Health Status | 2 | 2009 | 604 | 0.310 |
Why?
|
| Psychology, Child | 2 | 2008 | 42 | 0.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 596 | 0.300 |
Why?
|
| Double-Blind Method | 11 | 2021 | 2605 | 0.300 |
Why?
|
| Functional Laterality | 2 | 2010 | 315 | 0.300 |
Why?
|
| Autism Spectrum Disorder | 3 | 2022 | 369 | 0.300 |
Why?
|
| Schizophrenia | 2 | 2008 | 374 | 0.300 |
Why?
|
| Family Health | 3 | 2019 | 326 | 0.300 |
Why?
|
| Reversal Learning | 2 | 2018 | 7 | 0.300 |
Why?
|
| Biomedical Research | 2 | 2019 | 807 | 0.300 |
Why?
|
| Anorexia Nervosa | 2 | 2018 | 34 | 0.300 |
Why?
|
| Politics | 2 | 2018 | 75 | 0.300 |
Why?
|
| Age Factors | 11 | 2019 | 5384 | 0.300 |
Why?
|
| Family Therapy | 1 | 2007 | 38 | 0.290 |
Why?
|
| Neural Pathways | 3 | 2021 | 297 | 0.290 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 151 | 0.290 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2006 | 6 | 0.290 |
Why?
|
| Psychology, Adolescent | 1 | 2006 | 41 | 0.290 |
Why?
|
| Neurosurgical Procedures | 3 | 2023 | 610 | 0.290 |
Why?
|
| Adolescent Behavior | 3 | 2019 | 230 | 0.290 |
Why?
|
| Neuroimaging | 4 | 2023 | 405 | 0.280 |
Why?
|
| Brain Diseases | 2 | 2018 | 403 | 0.280 |
Why?
|
| Behavior | 1 | 2006 | 102 | 0.280 |
Why?
|
| Essential Tremor | 2 | 2023 | 85 | 0.270 |
Why?
|
| Benzodiazepines | 2 | 2004 | 171 | 0.270 |
Why?
|
| Drug Monitoring | 1 | 2008 | 337 | 0.270 |
Why?
|
| Imagination | 2 | 2016 | 23 | 0.270 |
Why?
|
| Telemedicine | 2 | 2022 | 473 | 0.260 |
Why?
|
| Caudate Nucleus | 2 | 2017 | 44 | 0.260 |
Why?
|
| Compulsive Behavior | 3 | 2011 | 36 | 0.260 |
Why?
|
| Radiosurgery | 3 | 2023 | 1332 | 0.260 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2018 | 14 | 0.250 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 259 | 0.250 |
Why?
|
| Intraoperative Period | 1 | 2004 | 247 | 0.240 |
Why?
|
| Drug Resistance | 4 | 2013 | 588 | 0.230 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 351 | 0.230 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2023 | 210 | 0.230 |
Why?
|
| Data Compression | 1 | 2023 | 14 | 0.230 |
Why?
|
| Analysis of Variance | 5 | 2014 | 2312 | 0.230 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2023 | 61 | 0.230 |
Why?
|
| Electromagnetic Fields | 2 | 2022 | 50 | 0.230 |
Why?
|
| Parturition | 1 | 2024 | 66 | 0.230 |
Why?
|
| Anti-Anxiety Agents | 1 | 2004 | 93 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2006 | 577 | 0.220 |
Why?
|
| Child, Preschool | 11 | 2022 | 16213 | 0.220 |
Why?
|
| Hyperacusis | 1 | 2022 | 5 | 0.220 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 928 | 0.210 |
Why?
|
| Reward | 1 | 2023 | 170 | 0.210 |
Why?
|
| Rheumatic Fever | 1 | 2002 | 18 | 0.210 |
Why?
|
| China | 5 | 2023 | 613 | 0.210 |
Why?
|
| Limbic System | 2 | 2013 | 30 | 0.200 |
Why?
|
| Antibodies, Bacterial | 1 | 2004 | 378 | 0.200 |
Why?
|
| Internal-External Control | 7 | 2019 | 110 | 0.200 |
Why?
|
| Angelman Syndrome | 1 | 2022 | 79 | 0.200 |
Why?
|
| Dystonia | 1 | 2023 | 163 | 0.200 |
Why?
|
| United Kingdom | 2 | 2020 | 257 | 0.200 |
Why?
|
| Treatment Failure | 4 | 2008 | 1392 | 0.190 |
Why?
|
| Electrophysiology | 1 | 2021 | 333 | 0.190 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 29 | 0.190 |
Why?
|
| Critical Care | 1 | 2007 | 777 | 0.190 |
Why?
|
| Conduct Disorder | 1 | 2020 | 26 | 0.190 |
Why?
|
| Self Report | 5 | 2023 | 776 | 0.190 |
Why?
|
| Personality Assessment | 4 | 2008 | 107 | 0.180 |
Why?
|
| Food | 2 | 2018 | 146 | 0.180 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 31 | 0.180 |
Why?
|
| Aged | 21 | 2022 | 70367 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2022 | 305 | 0.180 |
Why?
|
| Attitude to Health | 3 | 2009 | 466 | 0.180 |
Why?
|
| Faculty | 1 | 2021 | 133 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 165 | 0.180 |
Why?
|
| United States | 13 | 2023 | 15574 | 0.180 |
Why?
|
| Motivation | 3 | 2023 | 510 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2021 | 758 | 0.180 |
Why?
|
| Pyrrolidines | 1 | 2020 | 113 | 0.180 |
Why?
|
| Residential Treatment | 1 | 2019 | 12 | 0.170 |
Why?
|
| Photic Stimulation | 2 | 2015 | 260 | 0.170 |
Why?
|
| White Matter | 1 | 2022 | 195 | 0.170 |
Why?
|
| Behavioral Symptoms | 1 | 2019 | 32 | 0.170 |
Why?
|
| Anger | 1 | 2019 | 23 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2022 | 323 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2020 | 128 | 0.170 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 3755 | 0.160 |
Why?
|
| Touch Perception | 1 | 2018 | 20 | 0.160 |
Why?
|
| Psychotherapy | 1 | 2021 | 249 | 0.160 |
Why?
|
| Perception | 1 | 2021 | 353 | 0.160 |
Why?
|
| Neural Prostheses | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pandemics | 3 | 2022 | 1564 | 0.160 |
Why?
|
| Brain-Computer Interfaces | 1 | 2018 | 14 | 0.160 |
Why?
|
| Bioethics | 1 | 2019 | 70 | 0.160 |
Why?
|
| Habits | 1 | 2018 | 37 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 1650 | 0.160 |
Why?
|
| Data Mining | 1 | 2018 | 88 | 0.150 |
Why?
|
| Research Subjects | 1 | 2018 | 64 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2019 | 180 | 0.150 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 26 | 0.150 |
Why?
|
| Transportation of Patients | 1 | 2018 | 58 | 0.150 |
Why?
|
| Sensation | 1 | 2017 | 71 | 0.150 |
Why?
|
| N-Methylaspartate | 1 | 2017 | 50 | 0.150 |
Why?
|
| Checklist | 2 | 2022 | 124 | 0.150 |
Why?
|
| Cues | 1 | 2018 | 200 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 341 | 0.150 |
Why?
|
| Patient Preference | 1 | 2019 | 222 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 412 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2010 | 413 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2019 | 671 | 0.140 |
Why?
|
| Cytokines | 1 | 2006 | 2824 | 0.140 |
Why?
|
| Putamen | 1 | 2016 | 26 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2018 | 555 | 0.140 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2009 | 32 | 0.140 |
Why?
|
| Placebos | 3 | 2007 | 442 | 0.140 |
Why?
|
| Occipital Lobe | 1 | 2016 | 47 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 235 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 4945 | 0.130 |
Why?
|
| Epilepsy | 1 | 2023 | 881 | 0.130 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 68 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 418 | 0.130 |
Why?
|
| Observer Variation | 3 | 2007 | 671 | 0.130 |
Why?
|
| Myelin Sheath | 1 | 2016 | 151 | 0.130 |
Why?
|
| Avoidance Learning | 1 | 2015 | 95 | 0.130 |
Why?
|
| Psychophysics | 1 | 2014 | 19 | 0.120 |
Why?
|
| Amygdala | 1 | 2015 | 127 | 0.120 |
Why?
|
| Risk Factors | 8 | 2019 | 17622 | 0.120 |
Why?
|
| Benzamides | 1 | 2020 | 1834 | 0.120 |
Why?
|
| Chorea | 2 | 2006 | 35 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2019 | 676 | 0.120 |
Why?
|
| United States Food and Drug Administration | 4 | 2010 | 333 | 0.120 |
Why?
|
| Psychotropic Drugs | 2 | 2022 | 132 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2018 | 552 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 29996 | 0.120 |
Why?
|
| Fear | 1 | 2015 | 252 | 0.120 |
Why?
|
| International Cooperation | 1 | 2015 | 323 | 0.120 |
Why?
|
| Logistic Models | 5 | 2018 | 3450 | 0.120 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2010 | 79 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 9282 | 0.120 |
Why?
|
| Reaction Time | 1 | 2014 | 231 | 0.110 |
Why?
|
| Parent-Child Relations | 2 | 2019 | 258 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 948 | 0.110 |
Why?
|
| Electrodes, Implanted | 3 | 2023 | 183 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 161 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2013 | 81 | 0.110 |
Why?
|
| Electrodes | 2 | 2023 | 117 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2013 | 155 | 0.110 |
Why?
|
| Suicide, Attempted | 3 | 2010 | 132 | 0.110 |
Why?
|
| Stereotaxic Techniques | 1 | 2013 | 172 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 1219 | 0.100 |
Why?
|
| Prevalence | 4 | 2007 | 3272 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2008 | 1850 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2018 | 6104 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2020 | 1317 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2013 | 2804 | 0.100 |
Why?
|
| Syndrome | 2 | 2022 | 1351 | 0.100 |
Why?
|
| Obsessive Behavior | 1 | 2011 | 16 | 0.100 |
Why?
|
| Statistics as Topic | 3 | 2007 | 444 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2018 | 854 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1368 | 0.090 |
Why?
|
| Judgment | 1 | 2010 | 48 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 243 | 0.090 |
Why?
|
| Laughter | 1 | 2010 | 12 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2013 | 575 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 14913 | 0.090 |
Why?
|
| Oxygen | 1 | 2014 | 755 | 0.090 |
Why?
|
| Caregivers | 3 | 2022 | 680 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 3482 | 0.090 |
Why?
|
| Prognosis | 6 | 2015 | 21737 | 0.090 |
Why?
|
| Propylamines | 1 | 2009 | 12 | 0.080 |
Why?
|
| Electroencephalography | 2 | 2023 | 893 | 0.080 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 1032 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2010 | 12923 | 0.080 |
Why?
|
| Clomipramine | 2 | 2009 | 5 | 0.080 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2008 | 26 | 0.080 |
Why?
|
| Time Factors | 6 | 2020 | 12984 | 0.080 |
Why?
|
| Fluvoxamine | 2 | 2009 | 6 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 265 | 0.080 |
Why?
|
| Risperidone | 1 | 2009 | 62 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 501 | 0.080 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2008 | 7 | 0.080 |
Why?
|
| Compulsive Personality Disorder | 1 | 2008 | 12 | 0.080 |
Why?
|
| Drug Industry | 1 | 2008 | 88 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 34 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 63 | 0.080 |
Why?
|
| Neurobiology | 1 | 2008 | 25 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 6308 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1958 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2023 | 1531 | 0.070 |
Why?
|
| Desensitization, Psychologic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2008 | 59 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 187 | 0.070 |
Why?
|
| Feeding and Eating Disorders of Childhood | 1 | 2007 | 12 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2009 | 249 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 2325 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2010 | 374 | 0.070 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2006 | 19 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 38011 | 0.070 |
Why?
|
| Education | 1 | 2007 | 112 | 0.070 |
Why?
|
| Neuroanatomy | 1 | 2006 | 14 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 496 | 0.070 |
Why?
|
| Safety | 1 | 2008 | 464 | 0.070 |
Why?
|
| Patient Selection | 1 | 2014 | 2063 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 266 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 703 | 0.070 |
Why?
|
| Crime Victims | 1 | 2006 | 59 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 453 | 0.070 |
Why?
|
| Stress, Psychological | 3 | 2021 | 1001 | 0.070 |
Why?
|
| Amoxicillin | 1 | 2006 | 106 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 288 | 0.070 |
Why?
|
| Animals | 6 | 2021 | 59489 | 0.070 |
Why?
|
| Peer Group | 1 | 2006 | 136 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2020 | 1034 | 0.060 |
Why?
|
| Hydroxyzine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Streptolysins | 1 | 2004 | 7 | 0.060 |
Why?
|
| Buspirone | 1 | 2004 | 7 | 0.060 |
Why?
|
| Facial Expression | 1 | 2004 | 49 | 0.060 |
Why?
|
| Electroshock | 1 | 2004 | 46 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2004 | 25 | 0.060 |
Why?
|
| Deoxyribonucleases | 1 | 2004 | 46 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 438 | 0.060 |
Why?
|
| Carbohydrates | 1 | 2004 | 68 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2004 | 75 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 205 | 0.060 |
Why?
|
| Vagus Nerve | 1 | 2004 | 63 | 0.060 |
Why?
|
| Magnetics | 1 | 2004 | 109 | 0.060 |
Why?
|
| Computers | 1 | 2023 | 141 | 0.060 |
Why?
|
| Recurrence | 1 | 2011 | 4784 | 0.060 |
Why?
|
| Electromagnetic Radiation | 1 | 2022 | 4 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 116 | 0.050 |
Why?
|
| Light | 1 | 2023 | 247 | 0.050 |
Why?
|
| Psychophysiology | 1 | 2022 | 17 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 259 | 0.050 |
Why?
|
| Impulsive Behavior | 1 | 2023 | 142 | 0.050 |
Why?
|
| Ventral Striatum | 1 | 2021 | 19 | 0.050 |
Why?
|
| Disease Progression | 1 | 2013 | 6693 | 0.050 |
Why?
|
| Basal Ganglia | 1 | 2002 | 64 | 0.050 |
Why?
|
| Algorithms | 2 | 2023 | 3890 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 402 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 272 | 0.050 |
Why?
|
| Health Surveys | 1 | 2023 | 411 | 0.050 |
Why?
|
| Psychotherapy, Group | 1 | 2021 | 57 | 0.050 |
Why?
|
| Functional Neuroimaging | 1 | 2020 | 37 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3538 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2020 | 19 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 52 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 4745 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 5055 | 0.040 |
Why?
|
| Behavior Observation Techniques | 1 | 2019 | 6 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2021 | 100 | 0.040 |
Why?
|
| Defense Mechanisms | 1 | 2019 | 23 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2019 | 24 | 0.040 |
Why?
|
| Family Relations | 1 | 2020 | 88 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 2010 | 279 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 68 | 0.040 |
Why?
|
| Problem Behavior | 1 | 2019 | 35 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sex Factors | 2 | 2019 | 2156 | 0.040 |
Why?
|
| Duty to Recontact | 1 | 2018 | 4 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 33 | 0.040 |
Why?
|
| Raphe Nuclei | 1 | 2018 | 35 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 440 | 0.040 |
Why?
|
| Somatosensory Cortex | 1 | 2018 | 68 | 0.040 |
Why?
|
| Dopaminergic Neurons | 1 | 2018 | 52 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2018 | 73 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2010 | 6900 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 159 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 1159 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2010 | 417 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 673 | 0.040 |
Why?
|
| Individuality | 1 | 2017 | 58 | 0.040 |
Why?
|
| Florida | 2 | 2008 | 113 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 4337 | 0.040 |
Why?
|
| Language | 1 | 2019 | 310 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 271 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 898 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 457 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 361 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 695 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2420 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2302 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2015 | 1177 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 70 | 0.030 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2015 | 14 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 1307 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1554 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2015 | 31 | 0.030 |
Why?
|
| Facial Muscles | 1 | 2015 | 51 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2016 | 126 | 0.030 |
Why?
|
| Electromyography | 1 | 2015 | 227 | 0.030 |
Why?
|
| Hippocampus | 1 | 2020 | 921 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 1562 | 0.030 |
Why?
|
| Observation | 1 | 2014 | 51 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 561 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1316 | 0.030 |
Why?
|
| Paliperidone Palmitate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 804 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2992 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5713 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 686 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 544 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 562 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 2633 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2236 | 0.020 |
Why?
|
| Pregnancy | 1 | 2024 | 7549 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 588 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4976 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 33 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4903 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 16 | 0.020 |
Why?
|
| Government Programs | 1 | 2008 | 15 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 424 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 209 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2008 | 122 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2008 | 47 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1091 | 0.020 |
Why?
|
| Universities | 1 | 2008 | 160 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 1181 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 757 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2008 | 169 | 0.020 |
Why?
|
| Agonistic Behavior | 1 | 2006 | 10 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2007 | 117 | 0.020 |
Why?
|
| Loneliness | 1 | 2006 | 27 | 0.020 |
Why?
|
| Entropy | 1 | 2006 | 38 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 245 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2006 | 104 | 0.020 |
Why?
|
| Globus Pallidus | 1 | 2006 | 71 | 0.020 |
Why?
|
| Pharynx | 1 | 2006 | 153 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 418 | 0.020 |
Why?
|
| Seasons | 1 | 2006 | 341 | 0.020 |
Why?
|
| Public Health Administration | 1 | 2004 | 13 | 0.020 |
Why?
|
| Social Behavior | 1 | 2006 | 308 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 483 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2004 | 203 | 0.010 |
Why?
|
| Drug Approval | 1 | 2004 | 178 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2002 | 10 | 0.010 |
Why?
|
| Parenting | 1 | 2007 | 345 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 209 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 557 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2003 | 133 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 304 | 0.010 |
Why?
|
| Nausea | 1 | 2003 | 525 | 0.010 |
Why?
|
| Skull | 1 | 2002 | 225 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 787 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 510 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2003 | 556 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 831 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 1308 | 0.010 |
Why?
|